Replies to post #920 on GTC Biotherapeutics (fka GTCB)

[dodah_2]

urche...or anyone.... how is off-label use compensated? TIA

[DewDiligence]

>Note the reference to 92% off label use [of NovoSeven]<

This conflicts with the assertion on the CC that the large majority of NovoSeven use is on-label. Clearly, someone is mistaken.

[shears]

>Off-label use — This agent has been increasingly employed in an great number of "off- label" pediatric and adult settings [15]. In one multi-institutional audit of 701 patients identified as having received this product, 92 percent were for "off-label" settings, such as the prevention of bleeding in a patient with an existing coagulopathy and/or hepatic insufficiency and an impending surgical or invasive procedure [16]. Available information on the efficacy and side effects of recombinant human factor VIIa in such settings is largely anecdotal [15-21]:<

Could you provide a link?

Also, how common is herditary Factor VII deficiency. Can it be acquired, and how common is that?